Eli Lilly stumbles as weight-loss drug sales less than expected
Portfolio Pulse from
Eli Lilly's shares dropped 6.4% due to slower-than-expected sales growth of its weight-loss drugs, Mounjaro and Zepbound. The US market for incretins grew by 45%, but the company had anticipated faster growth. Lower inventory levels also contributed to lower-than-forecasted fourth-quarter revenue.
January 14, 2025 | 7:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's stock fell 6.4% due to slower-than-expected sales growth of its weight-loss drugs, Mounjaro and Zepbound. The US market for incretins grew by 45%, but the company had anticipated faster growth. Lower inventory levels also contributed to lower-than-forecasted fourth-quarter revenue.
The 6.4% drop in Eli Lilly's stock price is directly linked to the slower-than-expected sales growth of its weight-loss drugs, Mounjaro and Zepbound. The company's anticipation of faster growth in the incretin market was not met, and lower inventory levels further impacted revenue forecasts, leading to a negative short-term impact on the stock.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100